Chinless wonder as aesthetic specialist Kythera rises after floating at high end
This article was originally published in Scrip
Aesthetically-focused Kythera Biopharmaceuticals didn't rely on beauty alone to boost its $70.4 million initial public offering on 11 October - the late-stage status of the company's chin-thinning product and previously reported positive Phase III clinical trial results likely appealed to stock buyers who have been wary of earlier-stage investments.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.